The Information : Billionaire Databricks and Perplexity Co-Founder Pitches AI Re

Billionaire Databricks and Perplexity Co-Founder Pitches AI Researchers to Not Work for Big Tech

The billionaire co-founder of Databricks and Perplexity AI, Andy Konwinski, is singularly focused on plugging the years-long drain of talent from academia to Big Tech.

He wants to encourage academics to focus on publishing more openly available research, a reaction to the move by frontier AI companies to reduce the amount of AI research they publish as they race against one another to develop the best models and AI tools.

While Google, in particular, has long been known for its research publishing, a 2026 Stanford report noted that OpenAI, Anthropic and Google no longer disclose details about the software used to train their AI models, how much computing power they used, and the size of their training datasets — crucial points that could help researchers replicate the companies’ successes.

“There are many reasons—like fundamental, societal-level, defend-democracy reasons—that open research needs to survive,” Konwinski told me at the Association for Computing Machinery’s AI conference in San Jose. He pointed to a well-known Google research paper from 2017 that would later become the basis of today’s most popular AI models and chatbots.

Now, he said, there is an “aging generation of luminaries” that aren’t publishing research externally or sticking around in academia to “train up their replacement,” meaning there could be a future scarcity of AI talent, just as artificial intelligence technologies become more complex and crucial to national security.

Konwinski in June 2025 co-founded Laude Institute, a kind of Y Combinator for academic and research types with big ideas for breakthroughs in AI research. Laude Institute, which Konwinski put $100 million into, currently funds about 70 projects through grants of up to $10 million. One such project was Terminal-Bench, a collection of AI benchmarking tools created by researchers from Stanford and Laude Institute that’s become an industry standard for evaluating AI coding tools.

Another is Stanford’s Marin project, which is focused on coming up with more efficient, predictable ways to pre-train open source models that perform on par with frontier ones at a fraction of the cost by requiring fewer AI chips or fewer “runs” or rounds of training.

Konwinski said he chats with about one dozen PhD students every month from the top 20 universities in North America, with a particular focus on Stanford, Berkeley, MIT, and Carnegie Mellon. His pitch to them: Stay in academia as a PhD student, even if that means making less than $100,000 annually for a few years, rather than accepting a $1 million to $3 million compensation package from a tech firm. If they do that, and publish openly, Laude will fund their research so they can share technology breakthroughs with the world. Eventually, you’ll get offers for tens of millions of dollars from the same companies, he tells them.

“I can get you [researchers] to fifty million. I can get you to a hundred million,” he said. “The value you have is in your ability to make the breakthrough.”

Konwinski said he’s fighting an uphill battle as AI talent wars send compensation packages through the roof: “The trade-off‘s just getting so much harder ’cause people are having to say no to salaries that are unprecedented.”

Academia also has problems getting adequate resources to produce AI models. Universities used to need up to a $10 million budget for large AI research projects but the cost has soared to around $100 million in some cases, given the expenses linked to costly AI chips, Konwinski said.

Nvidia CEO Jensen Huang, for instance, thinks universities need $1 billion budgets for AI chips—an issue that Stanford visiting professor Anjney Midha grilled him about during a recorded class lecture last month.

“We are dying out here,” said Midha, referencing the university’s crimped ability to purchase Nvidia’s expensive graphics processing units.

“You don’t have the budget for $1 billion compute,” Huang responded. “You have to find a way to change the way you do budgeting, he said.

Meanwhile, Konwinski is doing what he can to encourage open research despite the challenges. Laude Institute is beginning to accept pledges from other technologists and said it has a commitment from Berkeley professor and Google distinguished engineer Dave Patterson.

He said open research “needs a heavyweight champion in the ring.”

“We're fostering this ecosystem of open research so that I can put forward a heavyweight contender in the arena with the closed labs, the closed models, the closed techniques.”

The Information : Fusion Startup Helion Nearly Triples Valuation to $15.5 Billio

Fusion Startup Helion Nearly Triples Valuation to $15.5 Billion in Thrive-led Round

The Takeaway
  • Fusion startup Helion’s valuation triples to $15.5 billion in Thrive-led round.
  • Helion’s Orion commercial fusion plant targets 2028 electricity production for Microsoft.
  • New capital will advance Omega capacitor facility and Orion commercial fusion plant.

Helion Energy, a nuclear fusion startup backed by OpenAI’s Sam Altman, still has to prove it can produce electricity to serve data centers and other customers. But investors seem confident it can deliver.

The Everett, Wash.–based company said it has raised $465 million in a funding round led by Thrive Capital, the investment firm founded by Josh Kushner, a big backer of OpenAI. Helion’s valuation after the investment was $15.5 billion, nearly triple the company’s $5.43 billion valuation during its prior round, announced in January 2025.

Other investors in the round include Alta Park Capital, Anti Fund, BoxGroup, Lux Capital, Peak XV Partners and Bill Ford, the executive chair of the Ford Motor Co. Many of the company’s existing investors, including Lightspeed Venture Partners, SoftBank Vision Fund 2 and Mithril Capital, also participated.

The steep increase in Helion’s valuation reflects the continued clamor among investors to put money into startups in and adjacent to the AI boom. While Helion has signed deals with customers, it has not yet begun to generate revenue from them. Like other clean energy startups, Helion is capitalizing on the explosion in demand for electricity driven in part by the proliferation of data centers.

In Helion’s case, its potential to provide a novel source of reliable, clean energy to AI companies attracted the early personal backing of Altman, who disclosed last month, during a trial in Elon Musk’s lawsuit against OpenAI, that he owned a third of Helion. In March, Altman stepped down from Helion’s board of directors, a move aimed at enabling the fusion company and OpenAI to explore future partnerships together, Helion’s CEO and founder David Kirtley said at the time.

Helion is building a generator that relies on nuclear fusion, the same process that powers the sun and other stars. In fusion, atoms combine under extreme heat and pressure, releasing energy in the process. It is the opposite of fission, the process of splitting atoms that is at the heart of traditional nuclear power plants. Both processes create energy without producing greenhouse gases, but fusion promises to do so without the safety risks of fission, such as meltdowns caused by runaway chain reactions and long-lasting radioactive waste.

In an interview, Kirtley said the new round of capital from investors will allow the company to advance two of its most important goals. The first of those is the completion of a manufacturing facility in Everett, dubbed Omega, to build capacitors, a critical component of Helion’s fusion generators, which store electrical energy.

The second goal is to begin operations at Orion, the company’s first commercial fusion power plant, which Helion has begun building in Malaga, Wash. Helion is aiming to begin producing electricity for customers at the plant in 2028 and has an agreement with Microsoft to ultimately deliver 50 megawatts of power for its data centers from the facility.

“What this means is we get to move faster,” Kirtley said of the new funding round. “This is accelerating what we’re building at Helion.”

The evidence of that building effort was on display on a recent tour of its operations in Everett, a city about a 45-minute drive north from Seattle. At the facility, Kirtley showed off a functional prototype of Helion’s fusion generator, Polaris, which is helping to drive the design of its Orion power plant. A multistory concrete box with walls 2 to 5 feet thick surrounds the generator. Inside the box, the hourglass-shaped generator is surrounded by a seemingly endless number of black power cables.

Kirtley was able to provide a tour of the box because it was a weekend, so Polaris was not operating and the machine was silent. The security and safety protocols for a fusion generator are very different from those for a nuclear fission reactor. Fission reactors use highly radioactive materials such as uranium for fuel. Nuclear power plants require large security perimeters in part to account for related safety risks.

In contrast, Polaris is housed in an unassuming industrial office park formerly occupied by a supplier to Boeing, which has a huge airplane factory nearby. The generator relies for fuel on a far less radioactive isotope, tritium, which doesn’t produce the same long-lived radioactive waste as uranium. On the recent tour of Helion’s generator, this reporter wore a dosimeter, a radiation monitoring device, which showed zero radioactivity present.

Because they pose fewer risks, fusion plants are generally more lightly regulated than traditional nuclear power plants, which have to navigate a thicket of federal rules. In Washington, for example, Helion is licensed by the state’s department of health, which also oversees equipment like the particle accelerators hospitals use in cancer treatments.

A big part of Helion’s physical presence in Everett is devoted to manufacturing the electronics that go into its generator, including its capacitors. Helion uses thousands of the devices to power the machines. One of the company’s biggest priorities is building as many of its capacitors as possible in-house to reduce its reliance on Chinese-made versions.

“We joke sometimes that we’re more of a power electronics company than a fusion company,” Kirtley said during the recent tour.

Still, Helion has to hit some significant milestones in the next couple of years to show it can be a viable long-term business. The company has missed key deadlines in the past. And more broadly, the concept of fusion has been talked about for so long as a source of cheap, clean electricity that there’s an old joke about it: The technology is 20 years away and always will be.

This week, Kirtley said the big increase in Helion’s valuation this week shows its investors believe the probability of the company hitting its goals has grown. “Fusion is going to be here a lot faster than a lot of people think,” he said.

Hedge Week : Point72 tops May hedge fund performance as multi-strat rivals post

Point72 tops May hedge fund performance as multi-strat rivals post mixed results

Steve Cohen’s Point72 Asset Management led performance among major hedge funds in May, extending a strong run of gains for the $50.7bn multi-strategy firm as the wider industry delivered a mixed month of returns, according to a report by Business Insider.

The report cites an unnamed person familiar with the matter as revealing that Point72 rose 2% in May, bringing year-to-date gains to approximately 10.5%. The result follows a 17.5% return in 2025, during which the firm outperformed several of its closest peers in the multi-strategy hedge fund space, including Millennium Management and Citadel.

Broader industry performance was also positive but more uneven. Millennium Management posted a 2.4% gain for May, lifting its 2026 returns to 6.1%, while Balyasny Asset Management moved into positive territory for the year after a 1.4% monthly gain.

Despite solid results among hedge funds, returns lagged behind broader equity markets, which rallied strongly on continued investor enthusiasm for technology and artificial intelligence-linked stocks. The S&P 500 rose 11% in May, following a gain of more than 5% in the month alone.

Not all managers posted gains. Walleye Capital and North Rock Partners recorded modest losses of 0.9% and 0.2% respectively over the month.

The performance snapshot highlights ongoing dispersion across the hedge fund industry, with multi-strategy platforms continuing to compete closely while navigating a market environment heavily influenced by equity momentum and sector concentration.

FT : Goldman Sachs expects SpaceX’s AI revenue to surge 100 times by 2030

Goldman Sachs expects SpaceX’s AI revenue to surge 100 times by 2030
Projections by Wall Street bank underpin the $1.78tn valuation group is pitching in IPO

SpaceX’s pitch to achieve a $1.78tn valuation in its initial public offering hinges on revenues at its AI unit surging by around 100 times by 2030, according to projections made by its lead investment bank Goldman Sachs.

Goldman expects revenues from SpaceX’s AI division to rise to $322bn by 2030 from $3.2bn in 2025, according to forecasts discussed by the Wall Street bank with a potential investor in the deal. SpaceX’s total revenue is expected to reach $474bn in 2030 from $18.7bn last year.

The bank’s lofty projections underscore the aggressive bets underpinning the AI investment boom by Big Tech firms that has propelled the US stock market to a series of record highs. Goldman’s model was verbally shared with the investor as SpaceX kicks off its IPO roadshow, in which bankers will seek to sell money managers on a deal that could raise up to $86bn.

The valuation of Elon Musk’s rockets-to-chatbot group rests on an assumption that its AI division xAI — which made a loss of $6.4bn in 2025 — has a total addressable market of $26.5tn, SpaceX’s IPO prospectus shows. That dwarfs the roughly $2tn total addressable market outlined for the group’s Starlink internet service and space operations.

Goldman’s projections show that the Wall Street bank expects revenues at SpaceX’s AI segment to rise 388 per cent to $15.6bn in 2026 compared with the year prior and reach $34.5bn in 2027. The estimates were confirmed by a person familiar with the matter.

SpaceX did not respond to a request for comment. Goldman declined to comment.

>>> US Gapping down

Gapping down
In reaction to earnings/guidance
:
  • PVH -21%, NTSK -18.6% (also CFO to retire), AVGO -14.8%, WOOF -11.8%, FIVE -10.7%, CRWD -10.1% (also 4-for-1 stock split), CIEN -6.1%, VEEV -5.6%, XE -2.5%, CMCO -2.1%, DSGX -1.2%
Other news:
  • ADCT -49.4% (topline data from its Phase 3 LOTIS-5 trial evaluating ZYNLONTA)
  • DDD -14.4% (prices offering of 16,393,443 shares of common stock at $3.05 per share)
  • AEVA -12.9% (prices follow-on offering of 4,494,382 shares of common stock at $22.25 per share)
  • JBIO -10.1% (prices 10.0 mln shares of common stock at $15.00 per share)
  • LGIH -4.9% (reports May closings)
  • BTSG -4.7% (prices secondary offering of 15.0 mln shares of common stock at $58.75 per share with company buyback)
  • CUE -4.3% (stock offering by selling shareholders)
  • TAC -4.1% (TAC to acquire two gas assets in Colorado for $1 bln from BX and concurrent $350 mln bought deal offering)
  • AVEX -2.5% (prices offering of 8.0 mln shares of common stock at $27.00 per share)
  • BMNR -2.5% (launches preferred stock offering to fund Ethereum strategy)
  • XPO -2% (LTL segment operating metrics for May)
  • ALVO -1.9% (resubmits U.S. applications for Simponi and Eylea biosimilars)

>>> US Gapping up

Gapping up
In reaction to earnings/guidance
:
  • TLYS +18.5%, CAL +10%, AI +0.8%, BKE +0.5% (May comps)
Other news:
  • VSTM +5.2% (FDA grants Fast Track Designation for VS-7375)
  • RCEL +4.7% (stockholders approved of the issuance of equity securities)
  • SNY +3.4% (launches 2026 employee stock purchase plan)
  • GLBE +3.1% (authorization of $500 mln share repurchase program)
  • ZSQR +2.6% (entered into a $50 mln committed equity forward purchase agreement with LucentHash / Data Part Capital, a trading name of Translucent Matter)
  • PHAR +2.1% (receives FDA acceptance for pediatric Joenja filing)
  • COST +2% (May same store comps)
  • MCHP +2% (received approval from the U.S. Department of Commerce's Bureau of Industry and Security for an export license authorizing the use of advanced technology under Export Control Classification Number 3E001 and related high-performance hardware under ECCN?3A001.a.7.b.)
  • GNK +1.9% (issues letter to shareholders)
  • NVS +1.7% (IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 years)
  • GHRS +1.6% (reports publication of Phase 2a Postpartum Depression Results)
  • ODC +1.5% (increases dividend; also authorizes 500,000 share repurchase program)
  • IPI +1.2% (increases share repurchase authorization to $50 mln from $35 mln)
  • TV +1.2% (issued zero-coupon mandatory convertible debentures into shares in the amount of $6,917,800,007.42 Mexican pesos)
  • EL +1.1% (increases expected charge related to restructuring program)
  • ADSK +1.1% (collaboration with Amazon Web Services)
  • ZG +1% (authorizes additional $1.25 bln in repurchases; also amends repurchase program to limit any shareholder to 45% voting power)
  • BIIB +1% (Biogen and UCB present additional Phase 3 lupus data for dapirolizumab pegol)

>>> US Research Calls I

Research Calls I
  • Upgrades:
    • Erasca (ERAS) upgraded to Neutral from Underperform at BofA Securities, tgt $16
    • Essent Group (ESNT) upgraded to Outperform from Market Perform at Keefe Bruyette, tgt $73
    • Expro Group (XPRO) upgraded to Buy from Neutral at Goldman
    • Karat Packaging (KRT) upgraded to Outperform from Market Perform at William Blair
    • Medtronic (MDT) upgraded to Buy from Neutral at BTIG Research, tgt $90
    • Murphy Oil (MUR) upgraded to Overweight from Sector Weight at KeyBanc, tgt $48
    • Oscar Health (OSCR) upgraded to Equal Weight from Underweight at Wells Fargo, tgt $20
    • Plains All American (PAA) upgraded to Neutral from Sell at Goldman, tgt $24
    • Plains GP Holdings (PAGP) upgraded to Neutral from Sell at Goldman, tgt $24
    • RTX (RTX) upgraded to Buy from Hold at Jefferies, tgt $220
    • UnitedHealth Group (UNH) upgraded to Buy from Neutral at BofA Securities, tgt $450
    • Venture Global (VG) upgraded to Overweight from Neutral at JPMorgan, tgt $17
  • Downgrades:
    • ADC Therapeutics (ADCT) downgraded to Sector Perform from Outperform at RBC Capital, tgt $2
    • Broadcom (AVGO) downgraded to Neutral from Outperform at Macquarie, tgt $437
    • CMS Energy (CMS) downgraded to Hold from Buy at Jefferies, tgt $74
    • Commercial Metals (CMC) downgraded to Equal Weight from Overweight at Wells Fargo, tgt $77
    • Ecopetrol (EC) downgraded to Neutral from Buy at Citigroup, tgt $18
    • EHang (EH) downgraded to Neutral from Buy at UBS, tgt $11.10
    • Ollie's Bargain Outlet (OLLI) downgraded to Accumulate from Buy at Gordon Haskett
    • PVH Corp. (PVH) downgraded to In Line from Outperform at Evercore ISI, tgt $79
    • Smith & Nephew (SNN) downgraded to Hold from Buy at Kepler Cheuvreux
  • Others:
    • Absci (ABSI) initiated with an Outperform at Leerink, tgt $12
    • Axalta Coating Systems (AXTA) reinstated with a Buy at Citigroup, tgt $44
    • Cipher Mining (CIFR) initiated with an Outperform at Bernstein, tgt $32
    • CoStar Group (CSGP) initiated with a Buy at Benchmark, tgt $45
    • FedEx Freight (FDXF) initiated with an Outperform at Evercore ISI, tgt $168
    • Opus Genetics (IRD) initiated with a Buy at Guggenheim, tgt $16
    • Pulse Biosciences (PLSE) initiated with a Buy at Canaccord, tgt $32
    • Radiopharm Theranostics (RADX) initiated with a Buy at H.C. Wainwright, tgt $6
    • Sherwin-Williams (SHW) reinstated with a Buy at Citigroup, tgt $355
    • TeraWulf (WULF) initiated with an Outperform at Bernstein, tgt $46

FT : Trafigura warns oil at ‘inflection point’ as Iran war stokes bumper half-ye

Trafigura warns oil at ‘inflection point’ as Iran war stokes bumper half-year profits
Commodity trader’s net profit more than doubles to $4.1bn for October to March period

Commodities trader Trafigura has warned that global energy markets are at an “inflection point” that could send prices sharply higher as it reported near-record first-half profits boosted by the war in the Middle East.

The group’s net profit for the six months to March 31 climbed to $4.1bn, more than double the same period last year — and the second highest in its history, just below the $5.5bn made in the first half of 2023 in the aftermath of Russia’s invasion of Ukraine.

Trafigura’s results are an early indication of how the trading houses that move raw materials around the world are expecting bonanza profits from the Iran war, which has largely shut the Strait of Hormuz since late February, disrupting the flow of as much as a fifth of the world’s oil.

While the privately held group’s profits announced on Thursday capture only the first month of the war, trading houses typically benefit from periods of disruption and volatility as they profit from dislocations in the prices of commodities between different geographic locations.

Trafigura and rivals such as Vitol, Mercuria and Gunvor all reported record profits during 2022 and 2023 after Russia’s full-scale invasion of Ukraine roiled energy markets.

Oil prices surged in the early days of the Iran war but since then prices have broadly been lower than many traders first anticipated, with Brent crude, the international benchmark, falling back below $100 a barrel.

Trafigura warned markets against complacency, with chief economist Saad Rahim arguing that the world had largely run through its “buffers” of fuel inventories and now stood “at an inflection point”.

The war in the Middle East has caused a production loss of about 14mn barrels per day, compared with pre-conflict levels, according to Rahim, who added that the price response did not reflect the magnitude of the energy crisis.

“The factors that have contained prices so far — elevated inventories, floating cargoes, co-ordinated SPR [strategic petroleum reserve] releases, a shoulder season, and demand destruction across Asia and Africa — have bought the market time, but are not a solution,” Rahim wrote in the report.

He pointed to low US petrol inventories as a particular concern, noting that these inventories are being drawn down at a record pace.

Even if a peace deal between the Trump administration and Tehran was reached soon, “restoring production and shipping flows to pre-conflict levels will, by most estimates, take months, not weeks”, Rahim added.

Trafigura chief executive Richard Holtum echoed Rahim’s view, saying “the pressures that have built up across commodity markets and global supply chains in recent months will take time to unwind”.

Trafigura, whose financial year runs until the end of September, said that during its first-half period its traders moved record volumes of oil and gas, equivalent to 8.7mn b/d, up 21 per cent from the same period a year prior.

The company’s involvement in Venezuela, where the US removed leader Nicolás Maduro in January, also contributed to its increased oil volumes, accounting for about 300,000 b/d.

Chief financial officer Stephan Jansma said the company had a particularly strong first quarter (ending December 31), its second-most profitable first quarter ever. Trafigura’s metals division benefited from the copper tariffs in place in the US, and its refineries reported unusually strong results in the quarter, the company said.

“A substantial portion of the period’s profits had already been secured before the conflict in the Middle East began at the end of February 2026,” Jansma wrote.

>>> Europe : Brokers Upgrades & Downgrades - 4th of June 2026 V2(+)

>>> Up
* Clas Ohlson Raised to Buy at SEB Equities; PT 425 kronor
* FLSmidth Raised to Buy at BofA
* Puma Raised to Buy at Citi; PT 35 euros
* Rockwool Raised to Buy at Nordea; PT 230 kroner
* Wartsila Raised to Neutral at Goldman; PT 34 euros

>>> Down
* Barry Callebaut Cut to Neutral at Goldman; PT 1,210 Swiss francs
* Lonza Cut to Sell at Intron Health; PT 440 Swiss francs (+)
* PSP Swiss Cut to Sell at Van Lanschot Kempen
* PVH Cut to Inline at Evercore ISI; PT $79
* Smith & Nephew Cut to Hold at Kepler Cheuvreux (+)

>>> Initiation
* Akzo Nobel Resumed Buy at Citi; PT 61 Swiss francs
* Autotrader Group PLC Rated New Buy at Goldman (+)
* Oeneo Rated New Outperform at Oddo BHF; PT 11.50 euros
* Prosus Rated New Neutral at Goldman (+)
* Rightmove Rated New Neutral at Goldman (+)
* Santhera Rated New Buy at Stifel; PT 25 Swiss francs
* Scout24 Rated New Buy at Goldman (+)
* Sylvania Platinum Rated New Outperform at RBC; PT 175 pence

>>> Call
* Goldman Cuts Barry Callebaut to Neutral on Industry Overcapacity (+)
* Defense Stocks Losing Steam as Catalysts Fade, Bernstein Says
* Oeneo Poised for Gradual Recovery, New Outperform at Oddo BHF
* Puma Raised to Buy at Citi on Major China Growth Opportunity
* Wartsila Raised to Neutral at Goldman on Capacity Increases (+)